Management of Osteoarthritis During the COVID‐19 Pandemic

Ragni, Enrico; Mangiavini, Laura; Viganò, Marco; Brini, A.T.; Peretti, Giuseppe M.; Banfi, Giuseppe; Girolamo, Laura de

doi:10.1002/cpt.1910

Cited by 22 publications

(25 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, OA cannot be reversed pharmacologically, but treatments can help relieve its symptoms. The medications most commonly used in OA treatment are intraarticular corticosteroids, topical and oral non-steroidal anti-inflammatory drugs (NSAID), duloxetine, and acetaminophen, often accompanied by physiotherapy and life style modification [4,5]. In the worst cases, when conservative approaches fail, arthroplasty remains the only option.…”

Section: Introductionmentioning

confidence: 99%

Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background In the last years, several clinical trials have proved the safety and efficacy of adipose-derived stem/stromal cells (ASC) in contrasting osteoarthritis (OA). Since ASC act mainly through paracrine mechanisms, their secretome (conditioned medium, CM) represents a promising therapeutic alternative. ASC-CM is a complex cocktail of proteins, nucleic acids, and lipids released as soluble factors and/or conveyed into extracellular vesicles (EV). Here, we investigate its therapeutic potential in an in vitro model of OA. Methods Human articular chondrocytes (CH) were induced towards an OA phenotype by 10 ng/ml TNFα in the presence of either ASC-CM or EV, both deriving from 5 × 105 cells, to evaluate the effect on hypertrophic, catabolic, and inflammatory markers. Results Given the same number of donor cells, our data reveal a higher therapeutic potential of ASC-CM compared to EV alone that was confirmed by its enrichment in chondroprotective factors among which TIMP-1 and -2 stand out. In details, only ASC-CM significantly decreased MMP activity (22% and 29% after 3 and 6 days) and PGE2 expression (up to 40% at day 6) boosted by the inflammatory cytokine. Conversely, both treatments down-modulated of ~ 30% the hypertrophic marker COL10A1. Conclusions These biological and molecular evidences of ASC-CM beneficial action on CH with an induced OA phenotype may lay the basis for its future clinical translation as a cell-free therapeutic in the management of OA.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the end to the COVID-19 spread is unanticipated, therapeutic regulation is needed for the management of RD patients to avoid added risk [8]. The increased susceptibility to the COVID-19 serious complications, make it indispensable to provide a roadmap to Egyptian rheumatologists.…”

Section: Discussionmentioning

confidence: 99%

“…The diverse clinical presentation of COVID -19 includes manifestations which can mimic rheumatic diseases (RDs) [6] or a flare [7]. Moreover, the pandemic may shape the treatment strategy of complex RDs [8]. It is paramount that continued clinical care of patients with chronic RDs who require hydroxychloroquine (HCQ) maintenance treatment must proceed [9].…”

Section: Introductionmentioning

confidence: 99%

Rheumatologists’ practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt

et al. 2020

View full text Add to dashboard Cite

The aim of this work is to trace how rheumatologists all over Egypt are approaching the COVID-19 pandemic and what changes it has brought about in the patients' care with special attention to its effect on vulnerable rheumatic disease (RD) patients. This survey further aims to help inform the rheumatology community about the changes in practice during the COVID-19 pandemic. The survey included 26 questions distributed to University staff members across Egypt members of the Egyptian College of Rheumatology (ECR). It takes 5-10 min to fill out. The practice setting of participating rheumatologists included University Teaching Hospitals that are the main rheumatology and clinical immunology service providers for adults and children RD patients. There was an overall agreement across the country in the responses to the survey that took a median time of 7 min to fill in. Potential changes in rheumatology outpatient practice by staff members evolved since the COVID-19 pandemic. None of the university rheumatology staff members has prescribed chloroquine or HCQ to prevent or treat COVID-19 in a non-hospitalized patient who was not previously on it. Twenty-three recommended decrease/avoid NSAIDs if the RD patient had confirmed COVID-19 or symptoms. There is an agreement to the key emerging frontline role of rheumatologists in treating COVID-19. During the pandemic, RD cases requiring admission were dealt with by several modified strategies. The overall agreement among the different university rheumatology departments during such critical situation has provoked the ECR to consider providing provisional guidelines for dealing with RD patients during this global catastrophe.

show abstract

“…shown that COVID-19 is more contagious than SARS-CoV seen in 2003, and that medical staff were also infected during the epidemic (5,6). Wu et al (7) first reported that timely antiviral treatment may slow the progression of COVID-19 caused by SARS-CoV-2 and improve the prognosis.…”

Section: Introductionmentioning

confidence: 99%

Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease

Dai

Zeng

Cui

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

In order to develop a novel scoring model for the prediction of coronavirus disease-19 (COVID-19) patients at high risk of severe disease, we retrospectively studied 419 patients from five hospitals in Shanghai, Hubei, and Jiangsu Provinces from January 22 to March 30, 2020. Multivariate Cox regression and orthogonal projections to latent structures discriminant analysis (OPLS-DA) were both used to identify high-risk factors for disease severity in COVID-19 patients. The prediction model was developed based on four high-risk factors. Multivariate analysis showed that comorbidity [hazard ratio (HR) 3.17, 95% confidence interval (CI) 1.96–5.11], albumin (ALB) level (HR 3.67, 95% CI 1.91–7.02), C-reactive protein (CRP) level (HR 3.16, 95% CI 1.68–5.96), and age ≥60 years (HR 2.31, 95% CI 1.43–3.73) were independent risk factors for disease severity in COVID-19 patients. OPLS-DA identified that the top five influencing parameters for COVID-19 severity were CRP, ALB, age ≥60 years, comorbidity, and lactate dehydrogenase (LDH) level. When incorporating the above four factors, the nomogram had a good concordance index of 0.86 (95% CI 0.83–0.89) and had an optimal agreement between the predictive nomogram and the actual observation with a slope of 0.95 (R2 = 0.89) in the 7-day prediction and 0.96 (R2 = 0.92) in the 14-day prediction after 1,000 bootstrap sampling. The area under the receiver operating characteristic curve of the COVID-19-American Association for Clinical Chemistry (AACC) model was 0.85 (95% CI 0.81–0.90). According to the probability of severity, the model divided the patients into three groups: low risk, intermediate risk, and high risk. The COVID-19-AACC model is an effective method for clinicians to screen patients at high risk of severe disease.

show abstract

Management of Osteoarthritis During the COVID‐19 Pandemic

Cited by 22 publications

References 120 publications

Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles

Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles

Rheumatologists’ practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt

Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease

Contact Info

Product

Resources

About